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Background: Previous study reported that sirolimus-eluting stents (SES) have little advantage over bare metal stents (BMS) for dialysis patients 
because of longer length and smaller diameter stenting due to “healthy to healthy” full cover stenting strategy in diffuse calcified lesions. We 
hypothesized that an approach of spot stenting with SES might result in superior clinical outcomes compared to full coverage of diffuse lesions with 
long or multiple SES in dialysis patients. 
Methods: Percutaneous coronary intervention using SES was performed in consecutive 52 dialysis patients with 63 de novo diffuse lesions (lesion 
length >20mm). We treated 44 lesions by full cover strategy (full stent coverage of the atherosclerotic lesion with multiple, overlapping stenting; FC 
group ) and 19 lesions by spot stenting strategy (spot stenting of hemodynamically significant parts of the lesion only; Spot group). 
Results: The baseline clinical and angiographic characteristics were similar between these two groups. The Spot group showed a shorter stent 
length compared with the FC group, however there were no significant differences in stent diameter between the 2 groups (mean stent length: 
25.8±7.6mm vs. 44.2±18.8mm, p=0.001, mean stent diameter: 3.05±0.37mm vs. 2.99±0.37mm, p=0.53). The rate of angiographic restenosis and 
target lesion revascularization (TLR) at 9 months in the FC group were significantly higher than the Spot group (restenosis: 36.4% vs. 10.5%; p<0.05, 
TLR: 31.8% vs. 10.5%; p<0.05). 
Conclusions: For dialysis patient, minimizing the stent length by spot stenting strategy could improve the subsequent clinical and angiographical 
result. Therefore, the comparative results suggest the principles that applied to the BMS era of larger diameter and shorter stent implantation are 
still warranted for dialysis patients, even in the Drug-eluting stents era.
